Compare MasterCard Inc (MA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Smith & Nephew plc — how do they compare? MasterCard Inc trades at $574.4 (market cap $499.38B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: MasterCard Inc is far larger — about 44.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Smith & Nephew plc for 120 Days on average.
| MA | SNN | |
|---|---|---|
Market Cap | $499.38B | $11.31B |
Volume | 1,862,680 | 1,050,005 |
Sector | Financials | Health |
52-Week High | $599.86 | $37.17 |
52-Week Low | $471.55 | $26.42 |
Typical Hold Time | 134 Days | 120 Days |
Enterprise Value | $512.41B | $14.35B |
Dividend Yield | 0.61% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $570.06, up 0.61% with a bullish technical signal and strong institutional interest. The company demonstrates robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining exceptional profitability margins. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $5.04 surpassing the $4.77 estimate. Analyst consensus remains strongly positive with 80% buy ratings and a $666.67 price target, representing 17% upside potential from current levels.
Mastercard presents a compelling growth opportunity with expanding digital payments adoption and strong execution, though faces risks from payment industry disruption and competitive threats. The stock's premium valuation (P/E 31.36) reflects high growth expectations that must be sustained. Near-term catalysts include Q3 2026 earnings and continued AI payment innovation, while regulatory scrutiny and economic sensitivity remain key monitoring points for investors.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
